- Home
- KALV
KALV
KalVista Pharmaceuticals Inc.
as 05-09-2025 2:38pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $24.83 | AVG Volume (30 days): | 507.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $15.50 | Next Earning Date: | 03-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Apr 9 '25 | Buy | $9.42 | 25,000 | $235,500.00 | 5,303,985 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Mar 6 '25 | Sell | $11.97 | 6,669 | $79,827.93 | 287,811 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 22 '25 | Sell | $10.02 | 2,394 | $23,987.88 | 102,940 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 21 '25 | Sell | $10.02 | 1,918 | $19,218.36 | 93,952 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 17 '25 | Sell | $9.82 | 5,104 | $50,142.72 | 287,811 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 17 '25 | Sell | $9.82 | 2,601 | $25,552.74 | 93,952 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 17 '25 | Sell | $9.82 | 3,125 | $30,700.62 | 102,940 | |
| Venrock Healthcare Capital Partners III, L.P. | KALV | 10% Owner | Feb 12 '25 | Buy | $9.28 | 161,700 | $1,498,661.00 | 5,303,985 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
Business Wire
7 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
9 days ago
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
Pharmaceutical Technology
a month ago
KalVista licenses commercialisation rights for HAE to Kaken in Japan
MT Newswires
a month ago
KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan
Business Wire
a month ago
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
Business Wire
a month ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
Clinical Trials Arena
a month ago
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.